Relevant bibliographies by topics / Ejection fraction

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Ejection fraction'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ejection fraction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ejection fraction"

1

Konstam, Marvin A., and François M. Abboud. "Ejection Fraction." Circulation 135, no. 8 (February 21, 2017): 717–19. http://dx.doi.org/10.1161/circulationaha.116.025795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shah, Dr Reena, Dr Sunita J. Solanki, Dr Prakash patel, and Dr Neeraj Singh Dr.Neeraj Singh. "Study of Incidence of Heart Failure with Reduced Ejection Fraction and Heart Failure with Normal Ejection Fraction." International Journal of Scientific Research 2, no. 10 (June 1, 2012): 1–2. http://dx.doi.org/10.15373/22778179/oct2013/104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Butler, Javed, Milton Packer, Gerasimos Filippatos, Joao Pedro Ferreira, Cordula Zeller, Janet Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, and Stefan D. Anker. "Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction." European Heart Journal 43, no. 5 (December 8, 2021): 416–26. http://dx.doi.org/10.1093/eurheartj/ehab798.

Full text
Abstract:
Abstract Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium–glucose cotransporter 2 inhibitor empagliflozin on heart failure outcomes. Methods and results A pooled analysis was performed on both the EMPEROR-Reduced and EMPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were grouped based on ejection fraction: <25% (n = 999), 25–34% (n = 2230), 35–44% (n = 1272), 45–54% (n = 2260), 55–64% (n = 2092), and ≥65% (n = 865). Outcomes assessed included (i) time to first hospitalization for heart failure or cardiovascular mortality, (ii) time to first heart failure hospitalization, (iii) total (first and recurrent) hospitalizations for heart failure, and (iv) health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The risk of cardiovascular death and hospitalization for heart failure declined progressively as ejection fraction increased from <25% to ≥65%. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure hospitalization by ≈30% in all ejection fraction subgroups, with an attenuated effect in patients with an ejection fraction ≥65%. Hazard ratios and 95% confidence intervals were: ejection fraction <25%: 0.73 (0.55–0.96); ejection fraction 25–34%: 0.63 (0.50–0.78); ejection fraction 35–44%: 0.72 (0.52–0.98); ejection fraction 45–54%: 0.66 (0.50–0.86); ejection fraction 55–64%: 0.70 (0.53–0.92); and ejection fraction ≥65%: 1.05 (0.70–1.58). Other heart failure outcomes and measures, including KCCQ, showed a similar response pattern. Sex did not influence the responses to empagliflozin. Conclusion The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patients with an ejection fraction ≥65%. Key Question How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? Key Finding The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions <25% to <65%, but it was attenuated in patients with an ejection fraction ≥65%. Take Home Message The consistency of the response in patients with ejection fractions of <25% to <65% distinguishes the effects of empagliflozin from other drugs that have been evaluated across the full spectrum of ejection fractions in patients with heart failure.
APA, Harvard, Vancouver, ISO, and other styles
4

Robotham, James L., Masao Takata, Michael Berman, and Yasuhiko Harasawa. "Ejection Fraction Revisited." Anesthesiology 74, no. 1 (January 1, 1991): 172–83. http://dx.doi.org/10.1097/00000542-199101000-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

SIEGEL, ALAN, J. CHRISTOPHER KUHN, HARTE CROW, and STEPHEN HOLTZMAN. "Gallbladder Ejection Fraction." Clinical Nuclear Medicine 25, no. 1 (January 2000): 1. http://dx.doi.org/10.1097/00003072-200001000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kevorkian, C. George, Seema V. Nambiar, and Diana H. Rintala. "Low Ejection Fraction." American Journal of Physical Medicine & Rehabilitation 84, no. 9 (September 2005): 655–61. http://dx.doi.org/10.1097/01.phm.0000176447.18405.50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Miller, Leslie W. "Cardiac Ejection Fraction." Journal of the American College of Cardiology 72, no. 6 (August 2018): 602–4. http://dx.doi.org/10.1016/j.jacc.2018.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

KALLOO, ANTHONY N., SAMUEL SOSTRE, GARY E. MEYERROSE, PANKAJ J. PASRICHA, and ZSOLT SZABO. "Gallbladder Ejection Fraction." Clinical Nuclear Medicine 19, no. 8 (August 1994): 713–19. http://dx.doi.org/10.1097/00003072-199408000-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Richmond, Bryan K., and Robert Fanelli. "Gallbladder Ejection Fraction." Journal of the American College of Surgeons 227, no. 2 (August 2018): 295–96. http://dx.doi.org/10.1016/j.jamcollsurg.2018.03.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Marmor, Alon, Diwakar Jain, and Barry Zaret. "Beyond ejection fraction." Journal of Nuclear Cardiology 1, no. 5 (September 1994): 477–86. http://dx.doi.org/10.1007/bf02961601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ejection fraction"

1

Mbasu, Richard Juma. "Distinguishing heart failure with preserved ejection fraction from heart failure with reduced ejection fraction using proteomics techniques." Thesis, University of Leicester, 2016. http://hdl.handle.net/2381/39013.

Full text
Abstract:
Heart failure is the second leading cause of morbidity and mortality in the world after cancer. In the UK, over 500,000 people are living with heart failure of which 30-40% die within 1 year of diagnosis. Some biomarkers for diagnosis and prognosis of heart failure have been established. However, they suffer from poor levels of accuracy and efficacy and their roles in clinical use is poorly understood. Thus, new biomarkers are needed. In this research, mass spectrometry based proteomics was used to profile patients plasma for clinical biomarker discovery due to its ability to perform both quantitative and qualitative protein profiling on clinical samples. Ninety samples from control, heart failure with preserved ejection fraction and heart failure with reduced ejection fraction subjects were used. Plasma protein profiling was performed using an optimised UPLC-IMS-DIA-MSE label free quantitation method. Bioinformatics analysis was used to analyse the changes observed in the protein profiles to identify potential biomarkers of heart failure. A novel method, termed mixed mode matrix was used for pilot study prior to main study with lipid removal agent. Samples were analysed using Waters Synapt G2S HDMS QToF mass spectrometer in triplicate on positive mode electrospray ionisation. Statistical comparisons of protein profiles was carried out using Progenesis LC-MS prior to data mining using SPSS, RapidMiner and SIMCA 14 to identify potential biomarkers. Thirty proteins were identified as potential biomarkers and shown to be involved in various pathophysiological processes leading to heart failure. ASL which plays role in nitrogen oxide production in the epithelium was upregulated in heart failure cohort. Conversely, GPX3 which scavenges free radicals in blood preventing apoptosis and necrosis of cells was downregulated in heart failure cohort. These two proteins were proposed as potential biomarkers for heart failure with preserved ejection fraction. Future studies to validate these biomarkers with the developed targeted LC-MS based MRM assay is needed.
APA, Harvard, Vancouver, ISO, and other styles
2

Phan, Thanh Trung. "The pathophysiology of heart failure with preserved ejection fraction." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/828/.

Full text
Abstract:
Our studies demonstrate that patients with HfpEF have impaired myocardial energetics as indicated by the diminished in vivo myocardial PCr/ATP ratio. Data acquired during semi-supine cycling exercise indicates that patients with HfpEF had a dynamic impairment of LV active relaxation. In addition, ventricular-vascular coupling ratio was unchanged during exercise in HfpEF patients in contrast to healthy controls where the ratio fell substantially during exercise. In addition, we found patients with HfpEF with normal LA dimensions had increased LA contribution during exercise as compared to controls. Furthermore, we showed patients with HfpEF exhibited contractile inefficiency as well as systolic and diastolic dyssynchrony as measured by speckle tracking imaging (STI). And that the LV anterior wall appears to be the most delayed segment. We also demonstrated that HfpEF patients exhibited chronotropic incompetence during peak exercise testing and abnormal HR recovery following exercise compared to age-gender-matched healthy controls and hypertensive patients. In a separate study, we showed that changes in LV torsion, untwist and LV strain and strain rate in patients with HfpEF at rest were similar to changes found in normal aging.
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Hitesh Chandrakant. "Renal denervation in heart failure with preserved ejection fraction." Thesis, Imperial College London, 2016. http://hdl.handle.net/10044/1/42993.

Full text
Abstract:
There are no treatments proven to significantly reduce heart failure hospitalisations or mortality in patients with heart failure with preserved ejection fraction (HFpEF). Activity of the sympathetic nervous system (SNS) is elevated in heart failure regardless of ejection fraction and may be an important target in HFpEF. Renal denervation (RDT) is a percutaneous technique that seeks to attenuate SNS activity. The aim of this thesis was to investigate the role of RDT in patients with HFpEF. A randomised (2:1) open-controlled trial with blinded endpoint analysis was planned. 10 228 patients were screened for the Renal DenervaTion in heart failure with Preserved Ejection Fraction trial (RDT-PEF), and ultimately 25 were randomised (17 received RDT and 8 were allocated to the open control arm). The primary endpoint was an improvement in a minimum of three out of the following six surrogate endpoints: Minnesota Living with Heart Failure questionnaire score, peak oxygen uptake on exercise, B-type natriuretic peptide, E/e' from echocardiography, left atrial volume from cardiac magnetic resonance imaging (CMR) and left ventricular mass from (CMR). The primary endpoint was not met but the study was underpowered. On post-hoc analysis there was an improvement in a composite score of all six endpoint in the RDT arm compared to the control arm at three months but this did not persist to 12 months. The study satisfied its safety endpoints. However, two patients required balloon angioplasty during the RDT procedure for significant renal artery spasm/oedema. RDT had no effect on blood pressure, renal function, vascular function, renin-angiotensin system or SNS activity. In summary, this thesis has shown that HFpEF is not as prevalent as reported. RDT did not improve quality of life, exercise function, biomarkers and left heart remodelling in HFpEF. The procedure was safe though not without complications in patients with HFpEF.
APA, Harvard, Vancouver, ISO, and other styles
4

Wright, Gabriel J. T. "Automated 3D echocardiography analysis : advanced methods and their evaluation on clinical data." Thesis, University of Oxford, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ma, Chao [Verfasser]. "Evaluation of mouse models of heart failure with preserved ejection fraction / Chao Ma." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2021. http://d-nb.info/123498489X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Niebauer, Josef. "Metabolic abnormalities in patients with chronic heart failure : assessment of cytokines, endotoxin, pro-oxidant substrates and exercise training." Thesis, Imperial College London, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.312600.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Carlbom, Charlotte. "Measurement of ejection fraction of the left ventricular - A comparison between echocardiography and isotope angiography." Thesis, Uppsala University, Department of Medical Biochemistry and Microbiology, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-9293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nilsson, Calle. "VO2peak/THV-ratio differ between heart failure patients with preserved ejection fraction and healthy controls." Thesis, Högskolan Kristianstad, Sektionen för lärande och miljö, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-17863.

Full text
Abstract:
Heart failure is a term for a group of complex symtoms characterized by reduced heart function. One of these syndromes, referred to as heart failure with preserved ejection fraction (HFpEF), has increased in prevalence compared to other types of heart failures during the recent years. A concern is the difficulty in diagnosing patients with HFpEF, since current tools are considered insufficient. The aim of this thesis was to examine Peak Oxygen Uptake (VO2peak) in relation to Total Heart Volume (THV) among heart failure patients with preserved ejection fraction (HFpEF, EF >40 %) compared to healthy controls. THV was acquired by delineating images acquired using cardiovascular magnetic resonance imaging, while VO2peak was measured in oxygen curves acquired from cardiopulmonary exercise tests. Ratios were calculated by dividing VO2peak with THV. In order to determine if blood hemoglobin concentration (b-Hb) could affect the ratio, ratios were adjusted to b-Hb using an adjusting factor. Mean THV was nearly 250 ml larger in HFpEF patients compared to the controls. Patients’ mean VO2peak was more than 1000 ml lower compared to the controls. Mean VO2peak/THV ratio calculated for the patients were less than half of that calculated for the controls. Adjusting the ratio to b-Hb did not affect the ratios significantly. The study was limited by the size of the test group, but the findings suggest that a VO2peak/THV ratio can be used to separate HFpEF patients from healthy controls.
Hjärtsvikt är ett begrepp för en grupp med komplexa symtom och kännetecknas av försämrad hjärtfunktion. Ett av dessa syndrom, hjärtsvikt med bevarad ejektionsfraktion (HFpEF), har ökat i prevalens jämfört med andra varianter av hjärtsvikt under de senaste åren. Ett problem är de svårigheter som finns med att diagnosticera patienter med HFpEF, då nuvarande verktyg inte är tillräckliga. Syftet med detta examensarbete var att undersöka maximalt syreupptag (VO2peak) i förhållande till total hjärtvolym (THV) bland hjärtsviktspatienter med bevarad ejektionsfraktion (HFpEF, EF >40 %) jämfört med friska kontroller. THV erhölls genom att utlinjera bilder tagna med hjälp av magnetisk resonanstomografi, medan VO2peak mättes i syrevolymkurvor som registrerats under ergospirometri-undersökningar. Index beräknades genom att dividera VO2peak med THV. För att undersöka huruvida halten hemoglobin i blodet (b-Hb) kunde påverka index justerades index mot b-Hb med hjälp av en justeringsfaktor. Medel-THV var nästan 250 ml större hos HFpEF-patienter jämfört med kontroller. Medel-VO2peak var mer än 1000 ml lägre hos patienterna jämfört med kontroller. Medel VO2peak/THV-index som beräknats för patienter var mindre än hälften så högt som index beräknat för kontroller. Att justera index mot b-Hb påverkade inte index signifikant. Studien begränsades av mängden deltagare, men fynden indikerar att VO2peak/THV-index kan användas för att skilja HFpEF-patienter från friska kontroller.
APA, Harvard, Vancouver, ISO, and other styles
9

Kasner, Mario [Verfasser]. "Novel echocardiographic modalities for evaluation of pathophysiology and diagnostic in heart failure with normal ejection fraction / Mario Kasner." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2015. http://d-nb.info/1172077010/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stoodley, Paul. "Echocardiographic measurement of cardiac function in breast cancer patients treated with anthracycline chemotherapy." Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/10526.

Full text
Abstract:
Introduction Anthracyclines are the cornerstone of breast cancer chemotherapy, however anthracyclines can be cardiotoxic. Left ventricular (LV) ejection fraction (LVEF) is the key echocardiographic measurement for monitoring cardiotoxicity, although LVEF has limitations. Myocardial strain imaging is new technology that may improve the measurement of cardiac function. The aim of this research was to study strain imaging for potentially earlier detection of dysfunction than LVEF, in breast cancer patients treated with anthracyclines. Method Anthracycline naïve breast cancer patients were prospectively studied; 78 short-term (over 3 months), and 50 in the intermediate-term (over 12 months). Patients were treated with standard anthracycline regimens. Echocardiograms were performed at 4 time points; 1) 7 days before chemotherapy, 2) 7 days after chemotherapy, 3) 6 months after, and 4) 12 months after chemotherapy. Results Global LV longitudinal systolic strain (GLS) was significantly reduced in the short-term (p<0.001), without a clinically significant reduction in LVEF. In the intermediate-term, strain values remained significantly reduced at 6 months (p<0.01), but normalized 12 months after chemotherapy. GLS at the 4 time points was: -19.0% ± 2.3%, -17.5% ± 2.3%, -18.2% ± 2.2%, -19.1% ± 1.9%. Persistently reduced strain at 12 months (in 16% of participants) was related to significantly higher anthracycline doses. Conclusion Significantly reduced LV systolic strain was detected in the short and intermediate-term after anthracyclines, without discernible changes in LVEF. In the majority, LV systolic dysfunction was transient: persistently reduced systolic strain was associated with higher anthracycline doses. Strain imaging is a more sensitive measure than LVEF in the short and intermediate-term monitoring of cardiac function after anthracycline chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Ejection fraction"

1

De Sutter, Johan, Piotr Lipiec, and Christine Henri. Heart failure: preserved left ventricular ejection fraction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0028.

Full text
Abstract:
Nearly half of all patients with heart failure present with a preserved left ventricular ejection fraction (HFPEF). HFPEF is a pathophysiologically and clinically heterogeneous disease with an overall similar outcome to heart failure patients with a reduced ejection fraction. It is predominantly seen in elderly patients and comorbidities such as obesity, diabetes, hypertension, a sedentary lifestyle, and myocardial ischaemia play important roles in its development. In this chapter the conventional echocardiographic hallmarks of HFPEF including a preserved ejection fraction, left ventricular hypertrophy, left atrial dilatation, diastolic dysfunction, and pulmonary hypertension are presented. For the evaluation of left ventricular diastolic dysfunction, it is important to keep in mind that no single echocardiographic parameter is sufficiently accurate and reproducible to be used in isolation to make a diagnosis of diastolic dysfunction. The value of newer techniques including three-dimensional echocardiography and longitudinal strain assessment for the diagnosis and follow-up of HFPEF patients are promising but require further evaluation. As exercise-induced dyspnoea may be the first manifestation of HFPEF, the role of exercise echo (or diastolic stress testing) with evaluation of exercise-induced changes in left ventricular filling pressure and pulmonary artery systolic pressure is also presented. This chapter ends with a discussion on the echocardiographic parameters that can be used for risk stratification and follow-up of HFPEF patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Katritsis, Demosthenes G., Bernard J. Gersh, and A. John Camm. Heart failure with preserved left ventricular ejection fraction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199685288.003.0805_update_003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Garcia, Mario J., and Allan L. Klein. Diastology: Clinical Approach to Heart Failure with Preserved Ejection Fraction. Elsevier, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hummel, Scott L., and Matthew C. Konerman. Heart Failure with Preserved Ejection Fraction, an Issue of Cardiology Clinics. Elsevier - Health Sciences Division, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Heart Failure with Preserved Ejection Fraction, An Issue of Heart Failure Clinics. Elsevier, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lam, Carolyn S. P. Heart Failure with Preserved Ejection Fraction, an Issue of Heart Failure Clinics. Elsevier - Health Sciences Division, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lancellotti, Patrizio, and Bernard Cosyns. Assessment of Diastolic Function. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713623.003.0005.

Full text
Abstract:
Diastole is the part of the cardiac cycle starting at aortic valve closure and ending at mitral valve closure. Evaluation of diastolic function by echocardiography is useful to diagnose heart failure with preserved ejection fraction, and regardless of ejection fraction, echocardiography can be used to estimate left ventricular filling pressure. Assessment of diastolic function includes analysis of left ventricular relaxation and compliance, left atrial and left ventricular filling pressures. This chapter describes the phases of diastole and covers the integrated approach of LV diastolic function through M-Mode and 2D/3D echocardiography, pulsed-wave Doppler echocardiography, and pulsed-wave tissue Doppler echocardiography.
APA, Harvard, Vancouver, ISO, and other styles
8

Gawlinski, Anna Frances. EFFECT OF POSITIONING ON VENOUS OXYGEN SATURATION IN THE CRITICALLY ILL PATIENT WITH A LOW EJECTION FRACTION. 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hausenloy, Derek, and Derek Yellon, eds. Coronary No-Reflow and Microvascular Obstruction. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0005.

Full text
Abstract:
• Following an AMI, the restoration of TIMI III coronary blood flow using thrombolytic therapy or primary percutaneous coronary intervention does not guarantee actual myocardial perfusion• In 40–60% of reperfused AMI cases, myocardial perfusion is impeded at the level of the capillaries due to microvascular obstruction (MVO)- a phenomenon termed coronary no-reflow• The presence of coronary no-reflow can be detected as impaired myocardial perfusion using non-invasive imaging modalities such as nuclear myocardial perfusion scanning, myocardial contrast echocardiography or contrast-enhanced cardiac magnetic resonance imaging• The presence of microvascular obstruction post-AMI is associated with a larger infarct size, impaired LV ejection fraction, adverse LV remodelling and poorer clinical outcomes• Current treatment strategies include; vasodilator therapy such as adenosine, calcium-channel blockers, and nitrates; distal protection to prevent microemboli; and glycoprotein IIb/IIIa inhibitors• Novel treatment strategies are required to prevent and treat coronary no-reflow, thereby improving myocardial perfusion, reducing myocardial infarct size, preserving LV ejection fraction, preventing LV remodeling and improving clinical outcomes.
APA, Harvard, Vancouver, ISO, and other styles
10

Smiseth, Otto A., Maurizio Galderisi, and Jae K. Oh. Left ventricle: diastolic function. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0021.

Full text
Abstract:
Evaluation of diastolic function by echocardiography is useful to diagnose heart failure with preserved ejection fraction by showing signs of diastolic dysfunction, and regardless of ejection fraction, echocardiography can be used to estimate left ventricular (LV) filling pressure. Diastolic dysfunction occurs in a number of cardiac diseases other than heart failure and mild diastolic dysfunction is part of the normal ageing process. The fundamental disturbances in diastolic dysfunction are slowing of myocardial relaxation, loss of restoring forces, and reduced LV chamber compliance. As a compensatory response there is elevated LV filling pressure. Slowing of relaxation and loss of restoring forces are reflected in reduction in LV early diastolic lengthening velocity (e?) by tissue Doppler. The reduced diastolic compliance is reflected in faster deceleration of early diastolic transmitral velocity by pulsed wave Doppler. Elevated LV filling pressure is reflected in a number of Doppler indices and in enlarged left atrium. This chapter reviews the physiology of diastolic function, the clinical methods and indices which are available, and how these should be applied.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Ejection fraction"

1

Nahler, Gerhard. "ejection fraction." In Dictionary of Pharmaceutical Medicine, 63. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Borlaug, Barry A. "Heart Failure with Preserved Ejection Fraction." In Management of Heart Failure, 213–30. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6657-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jackson, Alice M., and Pardeep S. Jhund. "Heart Failure with Reduced Ejection Fraction." In Textbook of Vascular Medicine, 383–95. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16481-2_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rush, Christopher J., and Mark C. Petrie. "Heart Failure with Preserved Ejection Fraction." In Textbook of Vascular Medicine, 397–408. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16481-2_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gallagher, James, and Michael Fong. "Heart Failure with Preserved Ejection Fraction." In Manual of Heart Failure Management, 59–71. London: Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-185-9_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hummel, Scott L. "Heart Failure with Preserved Ejection Fraction." In Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases, 193–203. London: Springer London, 2014. http://dx.doi.org/10.1007/978-1-4471-5198-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Moin, Danyaal S., and Gregory Lewis. "Heart Failure with Preserved Ejection Fraction." In Clinical Cases in Cardiology, 83–89. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-65804-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Isaza, Nicolas, and Pablo A. Quintero. "Heart Failure with Preserved Ejection Fraction." In Handbook of Outpatient Cardiology, 267–87. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-88953-1_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rao, Prashant, and Marwa A. Sabe. "Heart Failure with Reduced Ejection Fraction." In Handbook of Outpatient Cardiology, 251–66. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-88953-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shah, Amil M., and Jenine E. John. "Heart Failure with Recovered Ejection Fraction (HFrecEF) and Heart Failure with Midrange Ejection Fraction (HFmrEF)." In Heart Failure, 163–75. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9780429244544-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ejection fraction"

1

Marquez, F., J. Payne, E. Rowland, M. S. Modi, E. Rayyan, and S. Uppalapu. "What Ejection Fraction?" In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jaggi, Seema, William C. Karl, and Alan S. Willsky. "Dynamic estimation of left-ventricular ejection fraction." In IS&T/SPIE's Symposium on Electronic Imaging: Science and Technology, edited by Raj S. Acharya and Dmitry B. Goldgof. SPIE, 1993. http://dx.doi.org/10.1117/12.148635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fazry, Lhuqita, Asep Haryono, Nuzulul Khairu Nissa, Sunarno, Naufal Muhammad Hirzi, Muhammad Febrian Rachmadi, and Wisnu Jatmiko. "Hierarchical Vision Transformers for Cardiac Ejection Fraction Estimation." In 2022 7th International Workshop on Big Data and Information Security (IWBIS). IEEE, 2022. http://dx.doi.org/10.1109/iwbis56557.2022.9924664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Conrad, S. A., M. Jones, and P. Unkel. "Thermodilution cardiac output and ejection fraction: a mathematical analysis." In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1988. http://dx.doi.org/10.1109/iembs.1988.95123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mathur, Sumeet, Yingjin Wang, Keith R. Walley, and John H. Boyd. "CpG C Preserves Ejection Fraction In An Ischemic Model." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Afshin, Mariam, Ismail Ben Ayed, Ali Islam, Aashish Goela, Ian Ross, Terry Peters, and Shuo Li. "Estimation of the Cardiac Ejection Fraction from image statistics." In 2012 IEEE 9th International Symposium on Biomedical Imaging (ISBI 2012). IEEE, 2012. http://dx.doi.org/10.1109/isbi.2012.6235675.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lagopoulos, Athanasios, and Dimitrios Hristu-Varsakelis. "Measuring the Left Ventricular Ejection Fraction using Geometric Features." In 2022 IEEE 35th International Symposium on Computer-Based Medical Systems (CBMS). IEEE, 2022. http://dx.doi.org/10.1109/cbms55023.2022.00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mischi, M., A. H. M. Jansen, R. P. J. de Waard, and H. H. M. Korsten. "Contrast Ultrasound Methods for Left-Ventricle Ejection Fraction Measurements." In 2005 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2005. http://dx.doi.org/10.1109/iembs.2005.1615417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nasab, Maryam Tabatabaei. "Estimating cardiac output and ejection fraction using blood pressure signal." In 2014 International Congress on Technology, Communication and Knowledge (ICTCK). IEEE, 2014. http://dx.doi.org/10.1109/ictck.2014.7033494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pratiwi, Arvina Aulia, Riyanto Sigit, Dwi Kurnia Basuki, and Yudi Her Oktaviono. "Improved ejection fraction measurement on cardiac image using optical flow." In 2017 International Electronics Symposium on Knowledge Creation and Intelligent Computing (IES-KCIC). IEEE, 2017. http://dx.doi.org/10.1109/kcic.2017.8228602.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Ejection fraction"

1

Fukuta, Hidekatsu, Hiromi Hagiwara, and Takeshi Kamiya. Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a protocol for meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Sisi, Jingxian Zhang, Congying Liang, Xiaochuan Li, and Xiaoping Meng. High-Intensity Interval Training for Heart failure with preserved ejection fraction: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fukuta, Hidekatsu, Toshihiko Goto, and Takeshi Kamiya. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction: a protocol for meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2021. http://dx.doi.org/10.37766/inplasy2021.2.0025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lian, Zheng. Efficiency and safety of catheter-based renal denervation for heart failure with reduced ejection fraction: systemic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2020. http://dx.doi.org/10.37766/inplasy2020.6.0071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lew, Chong Zhi, and Ting Chi Yeh. Pediatric Extracranial Germ Cell Tumor: Clinical Perspective of Autologous Hematopoietic Cell Transplantation. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0081.

Full text
Abstract:
Review question / Objective: A large number of systematic reviews and meta-analyses (SRs/MAs) involving sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in the treatment of heart failure with preserved ejection fraction (HFpEF) have different outcomes. Condition being studied: The efficacy of SGLT-2is on HFpEF is currently a hot topic. However, the results of SRs/MAs conducted on relevant randomized controlled trials (RCTs) are inconsistent. We aim to conduct an umbrella review of existing SRs/MAs, to comprehensively evaluate study quality, and to incorporate calculated data from RCTs to update the results of primary outcomes.
APA, Harvard, Vancouver, ISO, and other styles
6

Krastev, Plamen. Dynamics of Left Ventricular Ejection Fraction under Revascularization of Patients with Acute Myocardial Infarction with ST-T Elevation and Single Coronary Artery Disease. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2021. http://dx.doi.org/10.7546/crabs.2021.05.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Yintang, Tong Gao, Chang Meng, Siyuan Li, Lei Bi, Yu Geng, and Ping Zhang. Sodium glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dong, Zhenyu, Muyassar Yusup, Yanmei Lu, and Baopeng Tang. The effectiveness of angiotensin receptor-neprilysin inhibitor in ventricular arrhythmia in patients with Heart Failure with Reduced Ejection Fraction: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jin, Xiandu, Hao wu, Min Cui, Liping Wei, and Xin Qi. Effects of oral Omecamtiv Mecarbil in patients with heart failure and a reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Treewaree, Sukrit, Narathorn Kulthamrongsri, Weerapat Owattanapanich, and Rungroj Krittayaphong. Sodium-glucose cotransporter-2 inhibitors reduce cardiovascular outcome and improve health status in Heart failure with preserved ejection fraction: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ejection fraction' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography